Modality.AI

In Conversation: "A Turning Point in ALS Trials" with Karl Kieburtz, MD, MPH https://lnkd.in/gmSCNnku Modality is building the most comprehensive audio/visual dataset of people living with ALS to enable biopharma organizations to run more informative clinical trials. New measures of what patients say and do can provide key insights into understanding the course of disease progression in natural history studies and treatment effects in clinical trials. In this 45-minute conversation, Modality CEO David "DSO" Suendermann-Oeft discusses advancements in digital endpoints and the potential to accelerate clinical research with special guest Karl Kieburtz, MD, MPH, the Co-Founder and Chair of Clintrex, and principal investigator for numerous multi-center trials in neurology over multiple decades. We are pleased to share this recording of their discussion over Zoom on International ALS/MND Day - June 21, 2024. #als #clinicaltrials

DSO wraps up a hectic couple of months in Basel today, Wednesday 26th.

This week, Modality's CEO, David "DSO" Suendermann-Oeft, will present at the Digital Biomarkers in Clinical Trials Summit, now in its seventh year. The summit brings into focus new digital health tools (DHT) that can supplement existing biomarker strategies to collect better data and improve the patient experience in clinical trials. DSO will be joining over 40 speakers and advisors, 300+ senior-level pharma, clinical trials, technology, and digital health executives in person on June 26, 2024, at Roche Headquarters in Basel. Be sure to connect with DSO if you’re attending. DSO's poster is titled: "When Words Speak Just as Loudly as Actions: Virtual Guide Based Remote Health Assessment Integrating What Patients Say with What They Do" Abstract: We present a unified multimodal dialog platform for the remote assessment and monitoring of patients' neurological and mental health. Tina, a virtual agent, guides participants through an immersive interaction wherein objective speech, facial, linguistic and cognitive biomarkers can be automatically computed from participant speech and video in near real time. Furthermore, Tina encourages participants to describe, in their own words, their most bothersome problems and what makes them better or worse through the Patient Report of Problems (PROP) instrument. We argue that combining these patient reports (i.e., what they say) with objective biomarkers (i.e., how they say it and what they do) can greatly enhance the quality of telemedicine and improve the efficacy of siteless trials and digital therapeutic interventions. Presenter: David Suendermann-Oeft, CEO, Modality https://lnkd.in/drySvksT #DigitalBiomarkerSummit #Roche #DigitalBiomarkers #DigitalHealth #neuroscience #digitalsafetymonitoring #digitalscreening #clinicalresearch #clinicaltrials #digitalendpoints #datascience #clinicalvalidation #decentralisedtrials #pharma #eCOA #roche

Modality CEO David "DSO" Suendermann-Oeft interviewed by Bio.News. "Modality.AI was one of the companies supported by the National Institutes of Health (NIH) SEED program chosen to present on the NIH Innovation Zone Stage at the 2024 BIO International Convention. Bio.News interviewed Modality.AI and the company’s founder and CEO, Dr. David Suendermann-Oeft, about their work and what their vision is for the future of AI-based neurological assessments." #als #clinicaltrials #bio2024 The National Institutes of Health Biotechnology Innovation Organization https://lnkd.in/g3zMRgPf

Please join us: Friday, June 21 at 11 AM PT for an important conversation: A Turning Point in ALS Trials https://lnkd.in/gwxGEJVv June 21 marks the northern hemisphere’s summer solstice – a turning point – and on this day, the ALS/MND community undertakes activities to express our hope for a turning point in the search for cause, treatment, and cure of ALS/MND. To drive a turnaround in trials for ALS and other neurological diseases, we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with partners such as MGH, Everything ALS, and recently, Verge Genomics, we're building the most comprehensive audio/visual dataset of people living with ALS. Please join us: Friday, June 21 at 11 AM PT for a 45-minute live webinar in which we will share highlights from our recent publications and discuss advancements in digital endpoints and the potential to accelerate clinical research with special guest Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex, and principal investigator for numerous multi-center trials in neurology. Please register here: A Turning Point in ALS Trials (you'll be prompted to "Sign in with Zoom" or "verify with email"). https://lnkd.in/gwxGEJVv #ALS #clinicaltrials

This week, June 17-20, Modality.AI CEO David "DSO" Suendermann-Oeft will attend and present at the ENCALS Meeting in Stockholm. ENCALS is a network of European universities and hospital centers active in clinical/research activities in ALS.  https://lnkd.in/ePWDEP_a Ahead of ENCALS he will attend a meeting hosted by Precision ALS, a pan-European organization working to build a “Patient Data Platform” so that research sites across Europe can work together towards a common goal of finding a treatment for ALS. https://lnkd.in/efvhRguC David will present two posters at ENCALS: "Multimodal Digital Biomarkers for Longitudinal Tracking of Speech Impairment Severity in ALS: An Investigation of Clinically Important Differences" and "How Consistent are Speech-Based Biomarkers in Remote Tracking of ALS Disease Progression Across Languages? A Case Study of English and Dutch" https://lnkd.in/gFXvFpAx #ALS #clinicalresearch #clinicaltrials

Beth Rogozinski, thanks for the pic! https://lnkd.in/gt4Py5gT #biotech #bio2024

Modality Webinar: A Turning Point in ALS Trials - Friday, June 21 at 11 AM PT https://lnkd.in/gwxGEJVv June 21st is the northern hemisphere’s summer solstice – a turning point – and on this day the ALS/MND community undertakes activities to express their hope for a turning point in the search for cause, treatment and cure of ALS/MND. To drive a turnaround in trials for ALS and other neurological diseases we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with MGH and Everything ALS and more recently Verge Genomics, Modality’s platform is building the most comprehensive audio/visual dataset of people living with ALS. We invite you to join us on Friday, June 21 at 11 AM PT for a 45-minute live webinar in which we will share highlights from our recent publications and discuss advancements in digital endpoints and the potential to accelerate clinical research with special guest Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex, and principal investigator for numerous multi-center trials in neurology. Please register here: A Turning Point in ALS Trials (you'll be prompted to "Sign in with Zoom" or "verify with email"). https://lnkd.in/gwxGEJVv #ALS #clinicaltrials

We are excited to announce that Modality.AI has joined the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) alongside the FDA, multiple top 10 pharmaceutical companies, and several academic institutions and innovators focusing on digital health measurement. #FDA #clinicaltrials #digitalhealth Continued... https://lnkd.in/g-9kG2yA

Today at BIO our CEO David Suendermann-Oeft (DSO) will share an update on Modality.AI. We welcome you to join DSO: Wednesday, June 5th at 2.45 pm in Presentation Theater 4. He will also present tomorrow, Thursday, June 6, at 12:15 PM in the NIH Booth (#825), in the U.S. Federal Area in Hall B. #BIOInternationalConvention #biotech #clinicaltrials